Firebrick Pharma's completion of Share Purchase Plan

Firebrick Pharma Limited (ASX:FRE) has successfully closed its Share Purchase Plan (SPP), raising $635,600 with approximately 100 shareholders participating. The Company has also received commitments for an additional $158,700 through a Shortfall Placement, bringing the total funds raised to approximately $0.8 million. The proceeds will be utilized to fund marketing initiatives for Nasodine Nasal Spray in Singapore and the US, as well as for working capital purposes.

Executive Commentary on Share Purchase Plan

'These SPP funds, amounting to approximately $0.8 million, are on the back of the $0.9 million we received last month in RDTI funds,' said Firebrick Executive Chairman, Dr Peter Molloy. 'I am pleased to say that we now have the necessary level of funding to confidently drive our planned marketing initiatives into 2025.'

Summary of Firebrick Pharma's Share Purchase Plan

Firebrick Pharma (ASX:FRE) has successfully completed its Share Purchase Plan, raising $635,600 with additional commitments of $158,700 through a Shortfall Placement. The total funds of approximately $0.8 million will be used to expand marketing initiatives for Nasodine Nasal Spray in Singapore and the US, as well as for working capital purposes. The Company's Executive Chairman, Dr Peter Molloy, expressed confidence in driving planned marketing initiatives into 2025 with the secured funding.